Use of An Advanced Technology to Obtain Optimal Glucose Management and Better Quality of Life Among People with Type 1 Diabetes

利用先进技术为 1 型糖尿病患者提供最佳血糖管理和更好的生活质量

• 批准号: 472049
• 负责人: WU ZEKAI
• 金额: $ 9.83万
• 依托单位: Institut de recherches cliniques de Montral
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-10-01 至 2025-10-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=472049&lang=en
• 关键词: Glucose Management; New Diabetes Technology (Automated Insulin Delivery); Nutrition; Patient-Oriented; Quality Of Life; Randomized Cross-Over Study; Real-World Study; Type 1 Diabetes

Over 300,000 Canadians live with type 1 diabetes (T1D), an autoimmune disease destroying vital insulin-producing cells. Insulin is necessary for survival and to regulate blood sugar levels. People with T1D must take insulin lifelong. Despite the advances

超过300,000名加拿大人患有1型糖尿病（T1D），一种自身免疫性疾病破坏了重要的胰岛素产生细胞。胰岛素对于生存和调节血糖水平是必需的。患有T1D的人必须服用胰岛素终生。尽管有进步